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Abstract
Inactivation of the von Hippel-Lindau tumor suppressor (VHL) is an archetypical tumor-initiating 
event in clear cell renal carcinoma (ccRCC), leading to the activation of hypoxia-inducible 
transcription factors (HIFs). However, VHL mutation status in ccRCC is not correlated with 
clinical outcome. Here we show that during ccRCC progression, cancer cells exploit diverse 
epigenetic alterations to empower a branch of the VHL-HIF pathway for metastasis, and the 
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strength of this activation is associated with poor clinical outcome. By analyzing metastatic 
subpopulations of VHL-deficient ccRCC cells, we discovered an epigenetically altered VHL-HIF 
response specific to metastatic ccRCC. Focusing on the two most prominent pro-metastatic VHL-
HIF target genes, we show that liberation from PRC2-dependent repressive histone methylation 
(H3K27me3) activates HIF-driven CXCR4 expression in support of chemotactic cell invasion, 
whereas loss of DNA methylation enables HIF-driven CYTIP expression to protect cancer cells 
from death cytokine signals. Thus, metastasis in ccRCC is based on an epigenetically expanded 
output of the tumor-initiating pathway.
The drivers of metastasis in certain cancers include genes and pathways that are 
mechanistically independent of the oncogenic mutations driving tumor initiation1–4. In other 
cancers, however, the pathways driving carcinoma formation additionally drive metastasis. 
One example of this alternative paradigm is ccRCC, a tumor type in which the VHL-HIF 
pathway drives both tumor initiation and metastasis5,6.
VHL is a classical gatekeeper inhibiting renal tumor initiation7–13. The main tumor 
suppressive function of VHL is its role in mediating the degradation of the hypoxia 
inducible factor 2 alpha (HIF2α, also know as endothelial PAS domain protein 1, EPAS1), 
which drives the expression of multiple target genes with tumorigenic functions5,14–16. 
Additionally, at least one HIF target gene, chemokine (C-X-C motif) receptor 4 (CXCR4), is 
a direct mediator of metastatic colonization1,6,17,18. Therefore, it was previously suggested 
that VHL loss might directly lead to metastatic tumor phenotypes through HIF activation6. 
This model, however, is challenged by the striking clinical facts that most VHL-negative 
ccRCCs never metastasize19, and that VHL mutation status does not correlate with poor 
disease outcome20,21, even though CXCR4 expression does6,22.
We used the combined power of new experimental model systems and large clinical data 
sets to test the hypothesis that the activation of CXCR4 and other metastatic genes 
downstream of VHL-HIF is enabled by epigenetic events in metastatic subpopulations of 
renal cancer cells.
RESULTS
ccRCC metastasis model with clinically relevant correlates
We isolated metastatic subpopulations of the VHL-deficient ccRCC cell line 786-O, 
originally derived from a primary tumor of an individual with widely metastatic disease 
(Supplementary Fig. 1a)23. The parental cell line contained rare clones that upon intravenous 
inoculation into mice were capable of forming rapidly growing metastases in the lungs, the 
most frequent site of ccRCC metastasis19 (Supplementary Fig. 1b). Isolation of cells from 
these lesions yielded variants (786-M1A and M1B) that were ~100-fold enriched for lung 
colonizing activity (Fig. 1a and Supplementary Fig. 1c,d). Second generation derivatives 
(786-M2A and M2B) recapitulated the behavior of the 786-M1 cells (Fig. 1a and 
Supplementary Fig. 1c,d). The enhanced metastatic phenotype was not associated with 
changes in cell proliferation in vitro (Supplementary Fig. 1e). The 786-M1A derivatives 
were more metastatic to the lung also from the orthotopic site (Fig. 1b). Orthotopic tumors 
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formed by 786-O cells displayed a high-grade ccRCC histology with prominent epithelioid 
features, whereas the metastatic 786-M1A cells showed areas of epithelioid ccRCC and also 
areas of sarcomatoid features (Fig. 1c and Supplementary Fig. 1f). Lung metastatic nodules 
presented only sarcomatoid histology (Fig. 1c and Supplementary Fig. 1f). All the cell lines 
tested were also more aggressive in forming osteolytic bone metastasis (Fig. 1d,e and 
Supplementary Fig. 2a,b) and more slowly progressing invasive lesions in the brain (Fig. 
1f,g and Supplementary Fig. 2c), organs commonly affected by ccRCC19,24.
We used genome wide transcriptional profiling to identify 155 genes associated with this 
metastatic phenotype (Supplementary Table 1). In an unsupervised hierarchical clustering 
analysis of three independent human data sets comprising 758 samples (TCGA consortium, 
GSE2109 and GSE3538)25, this 155 gene set was able to identify tumor subgroups that had 
an expression profile resembling that of the metastatic cells (Supplementary Fig. 3a–c). 
These data sets were derived from surgically removed untreated primary ccRCCs, with the 
exception of three tumors in the GSE2109 and seven tumors in the TCGA data sets that had 
received prior treatment. The unfiltered 155 gene set showed clinically significant clustering 
of human primary tumors, even though it was likely to contain gene expression events that 
were specific to our cell lines. Therefore, we used the GSE2109 data set to filter out genes 
that behaved discordantly between our experimental model and clinical samples. This step 
reduced the number of genes to 50 yielding a classifier (RMS50) that provided a tight 
correlation with clinical outcome in both the TCGA and GSE3538 cohorts (Fig. 1h and 
Supplementary Fig. 3d–g).
Altered VHL-HIF response in metastatic ccRCC cells
One of the most highly overexpressed genes in the metastatic cells was CXCR4 (52-fold; 
Supplementary Table 1), which was of interesting for two reasons. Firstly, CXCR4 
expression correlates with poor prognosis and metastasis in ccRCC6,22,26. Secondly, CXCR4 
is induced upon VHL loss6,27. We confirmed the higher expression of CXCR4 by 
quantitative RT-PCR and also showed that this induction was strongly dependent on VHL 
loss (Fig. 2a). Furthermore, CXCR4 mRNA levels were associated with disease progression 
in a cohort of mostly early stage ccRCC samples collected in our institution (Fig. 2b). The 
expression of vascular endothelial growth factor A (VEGFA) and adrenomedullin (ADM), 
both known VHL-HIF target genes28, remained unchanged (Fig. 2c). Also, there were no 
differences in VHL mutation status (data not shown) or HIF2α protein expression 
(Supplementary Fig. 4a). These findings suggested that clonal derivatives of a single VHL-
mutant cell could display significant variation in the VHL-HIF pathway transcriptional 
output and that this was associated with different tumor phenotypes.
To determine whether this alteration in the VHL-HIF signal output included genes other 
than CXCR4, we performed gene expression profiling. Of the 137 genes that were 
significantly regulated by VHL in the 786-M1A cells (Supplementary Table 2), 37 were also 
present in the 155 gene set (Fig. 2d). This overlap was more than what would be expected by 
chance alone and included both up- and down-regulated genes. Also, these 37 overlapping 
genes were significantly enriched in two (of the four possible) categories: 1) induced by 
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VHL loss and upregulated in metastatic cells or 2) repressed by VHL loss and 
downregulated in metastatic cells (Supplementary Fig. 4b).
As HIFs are primarily transcriptional activators29, we focused on the 12 genes that were 
both upregulated upon VHL loss and had higher expression in the metastatic cells. To avoid 
possible confounding effects caused by tumors in which the HIF-pathway was not activated, 
we analyzed the expression of these VHL-regulated genes in a set of VHL-mutant primary 
ccRCC specimens30. VHL mutation status was not associated with RMS50-status 
(Supplementary Fig. 4c), but a subset of metastasis-associated VHL-HIF target genes, 
namely CXCR4, cytohesin 1 interacting protein (CYTIP), SLAM family member 8 
(SLAMF8), chemokine (C-X-C motif) receptor 7 (CXCR7), and latent transforming growth 
factor beta binding protein 1 (LTBP1) had significantly higher expression in RMS50-
positive VHL-negative tumors (Supplementary Fig. 5a). Other genes, such as VEGFA and 
ADM, showed no difference (Supplementary Fig. 5b). We confirmed the expression of these 
genes by qRT-PCR in our cell line model (Fig. 2e). The expression of these genes was 
dependent on HIF2α (Fig. 2f). Protein analysis confirmed CXCR4 and CYTIP 
overexpression in the metastatic cells (Supplementary Fig. 5c,d).
To determine the generality of these findings, we utilized two additional cell line systems. 
One of them (RFX-631) spontaneously formed robust lung metastasis with a mixed 
epithelioid and sarcomatoid histology (Supplementary Fig. 6a). The other cell line (OS-
RC-2) was more indolent and gave rise to metastatic OS-LM1 variants after in vivo selection 
(Supplementary Fig. 6b–d). The OS-LM1 metastatic nodules were of the classic clear cell 
morphology with some regions containing cells with eosinophilic cytoplasm (Supplementary 
Fig. 6e). The expression of all five genes was dependent on VHL loss at least in one 
additional model system, and CXCR4, CYTIP and LTBP1 scored in both RFX-631 and OS-
LM1 cells (Fig. 2g,h). CXCR4, CYTIP, LTBP1 and SLAMF8 all showed varying degrees of 
overexpression in OS-LM1 cells when compared to the parental OS-RC-2 cells 
(Supplementary Fig. 6f), confirming that their expression was more generally selected for in 
cells with metastatic potential.
In conclusion, the VHL-HIF pathway not only drives ccRCC initiation but also the 
expression of several genes that are associated with ccRCC metastasis (Fig. 2i).
Expanded HIF signal output activates mediators of metastasis
VHL reintroduction strongly inhibited 786-M1A lung colonizing activity (Fig. 3a). Among 
the VHL-HIF-dependent genes associated with metastasis in our model systems, CXCR4 
and CXCR7 are G protein-coupled receptors for the chemokine CXCL121,17,18. CYTIP is a 
~40kDa intracellular protein that can enhance NFAT/AP1 transcriptional responses31, 
modulate cell adhesion and migration32–34, and support stem cell fitness32. LTBP1 is a large 
extracellular protein that regulates TGF-β activation35. SLAMF8 is a cell surface receptor 
normally expressed in activated macrophages. To prioritize our functional analysis, we 
focused on CXCR4, CYTIP and LTBP1, genes consistently associated with metastasis across 
all cell line systems (Figs. 2a, 2e and 2g,h). LTBP1 was not essential for lung metastasis in 
the 786 model (Supplementary Fig. 7a,b), possibly due to compensation by LTBP4 
(Supplementary Table 1) or other LTBP family members, whereas knockdown of CYTIP or 
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CXCR4 inhibited by 10-fold the lung colonizing activity of 786-M1A cells (Fig. 3b and 
Supplementary Fig. 8a,b). Combinatorial knockdown of both genes further reduced the lung 
metastatic burden (Fig. 3b). Both CYTIP and CXCR4 cDNA constructs also enhanced the 
metastatic potential of 786-O cells (Fig. 3c and Supplementary Fig. 8c). Combinatorial 
knockdown of CYTIP and CXCR4 strongly inhibited OS-LM1 lung colonization as well 
(Fig. 3d and Supplementary Fig. 8d).
To determine the cellular mechanisms through which CXCR4 and CYTIP contributed to 
metastasis, we tested their effects on phenotypes relevant to metastasis in vitro. As 
reported6, CXCR4 mediated CXCL12 chemotactic migration in metastatic 786-M1A cells, 
with associated changes in the Erk phosphorylation status (Fig. 3e and Supplementary Fig. 
9a,b). The CXCR4 inhibitor AMD3100 blocked the chemotactic phenotype in vitro (Fig. 3e) 
and reduced metastasis formation in vivo (Fig. 3f).
Metastasis assays suggested a role for CYTIP in the early steps of lung colonization 
(Supplementary Fig. 9c). However, CYTIP knockdown also inhibited bone metastasis (Fig. 
3g). As extravasation through sinusoid capillaries in the bone marrow is not thought to be 
rate limiting for bone metastasis, we reasoned that CYTIP might support the survival of 
disseminating cancer cells. Indeed, CYTIP knockdown significantly reduced cancer cell 
viability in the presence of TRAIL cell death cytokine (Fig. 3h).
DNA demethylation allows CYTIP expression in metastatic ccRCC
We used the two functionally validated target genes, CXCR4 and CYTIP, to investigate the 
basis of the altered VHL-HIF-response. We found little evidence for genomic amplification, 
altered mRNA stability, or increased promoter activity as being the explanation for the 
increased expression of these genes (Supplementary Fig. 10a–c). We therefore asked 
whether epigenetic changes in transcriptional accessibility of these loci36 could explain our 
observations. Indeed, the promoter regions of CXCR4 and CYTIP, but not that of VEGFA, 
were more sensitive to DNase I in the metastatic cells (Supplementary Fig. 11a,b). This 
difference remained after enforced expression of VHL (Supplementary Fig. 11b), showing 
that DNase sensitivity was not simply associated with transcriptional activity.
Mutations in epigenetic regulators make these genes attractive candidates as mediators of 
epigenetic remodeling in ccRCC30,37. In our analysis, RMS50 positivity was not associated 
exclusively with PBRM1, SETD2 or JARID1C mutant tumors (Supplementary Fig. 12), and 
these genes showed no mutational differences between our parental and metastatic cells. 
Also, inhibition of PBRM1, JARID1C or SETD2 did not result in consistent changes in 
CXCR4 expression (Supplementary Fig. 13).
Genome-wide assessment of DNA methylation patterns revealed that, in general, genes that 
were overexpressed in the metastatic cells had higher levels of DNA methylation near the 
transcription start site (TSS) when compared to non-changed genes or random genomic loci 
(Supplementary Fig. 14a). This methylation was reduced in the metastatic cells to the level 
of non-changed genes. The downregulated genes showed methylation levels comparable to 
non-changed genes both in the parental and metastatic cells (Supplementary Fig. 14b). 
Among genomic regions with the greatest DNA methylation difference between the 
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metastatic and non-metastatic cells, 756 out of 772 regions (98%, P < 1.0 × 10−10) had 
lower methylation in the metastatic cells (Fig. 4a). Of the 756 regions with reduced DNA 
methylation, 18 were associated with upregulated genes in the 155 gene set (P = 5.6 ×10−7). 
The vast majority was not, however, associated with transcriptional changes. CYTIP showed 
reduced methylation near the TSS, whereas CXCR4 showed low levels of DNA methylation 
across the whole gene locus and no change (Fig. 4b and Supplementary Fig. 15a). We 
confirmed these results with targeted analysis of the most highly induced RMS50 genes 
(Supplementary Fig. 15b).
To evaluate the role of DNA methylation in CYTIP expression, we treated 786-O cells with 
the DNA methyltransferase inhibitor 5′-aza-deoxycytidine (5DC). This led to DNA 
demethylation (Supplementary Fig. 15c) and robust expression of CYTIP, but not CXCR4, 
ADM or VEGFA (Fig. 4c). CYTIP induction was dependent on VHL inactivation (Fig. 4c), 
and it remained high two weeks after 5DC treatment (Supplementary Fig. 15d). 
Concordantly, analysis of DNA methylation in 78 untreated human primary ccRCC 
specimens detected little methylation at the CXCR4 promoter (Fig. 4d), whereas CYTIP 
promoter contained abundant DNA methylation (Fig. 4e). We observed a significant inverse 
correlation between tumor grade and stage with CYTIP methylation (Fig. 4e and 
Supplementary Fig. 16). Low levels of CYTIP methylation correlated with poor disease 
outcome (Fig. 4f). Thus, changes in CYTIP DNA methylation were associated with 
aggressive tumor phenotypes both in our experimental model and clinically.
Loss of H3K27me3 repressive mark at the CXCR4 locus
The involvement of DNA methylation in CYTIP but not in CXCR4 regulation implied that 
multiple mechanisms of VHL-HIF output amplification are coselected during ccRCC 
progression. The CXCR4 locus in stem cells is marked by a bivalent histone H3 modification 
with trimethylated lysines 4 and 27 (H3K4me3 and H3K27me3, respectively)38. H3K4me3 
is generally a mark of transcriptionally active genes, and H3K27me3 of repressed genes39. 
ChIP-seq experiments revealed that, in general, 786-M1A cells contained more H3K4me3 
near upregulated genes in the 155 gene set when compared to the parental cells, whereas the 
opposite was true for the downregulated genes (Supplementary Fig. 17a). H3K27me3 
followed an inverse pattern, where genes with higher expression in the metastatic cells 
showed lower levels of H3K27me3 and vice versa (Supplementary Fig. 17b), relative to the 
control experiment with IgG (Supplementary Fig. 17c). In individual genes, H3K4me3 
followed in most cases the pattern expected of transcriptionally active genes, as shown for 
CXCR4 and CYTIP (Fig. 5a). For H3K27me3, on the other hand, only few genes, including 
CXCR4, drove the observed global difference between the cell lines (Fig. 5b). The majority 
of genes, including CYTIP (Fig. 5b), contained H3K27me3 levels comparable to the 
negative IgG control (Supplementary Fig. 17d).
Next we identified genomic loci that showed the greatest difference in H3K4me3 and 
H3K27me3 enrichment between the parental and metastatic cells, irrespective of their 
expression pattern. For H3K4me3 this revealed a uniform distribution of both higher and 
lower enrichment in the metastatic cells (Supplementary Fig. 18a). In contrast, for 
H3K27me3 the distribution was strongly skewed, with the most differentially enriched 
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regions having a lower level of H3K27me3 in the metastatic cells (Supplementary Fig. 18b). 
Among the 155 metastasis-associated genes, we observed a strong correlation between 
changes in H3K4me3 and gene expression, especially for the genes that were activated in 
the metastatic cells (Supplementary Fig 18c,d). For H3K27me3, however, no significant 
overlap was seen (Supplementary Fig. 18c), the only shared gene between the 74 most 
differentially changed regions and the genes upregulated in metastatic cells being CXCR4. 
Hence, the majority of H3K27me3 demethylation events do not automatically lead to 
transcriptional activation.
We confirmed these ChIP-seq results by ChIP-qPCR and tested the effects of VHL-
reintroduction on the histone modification status of CXCR4 and CYTIP. Whereas the high 
H3K4me3 levels were strongly dependent on VHL-HIF pathway activity (Fig. 5c), 
H3K27me3 remained unchanged (Fig. 5d).
Loss of PRC2-mediated repression of CXCR4 in metastatic ccRCC
H3K27me3 is a hallmark of gene repression by Polycomb Repressive Complex 2 (PRC2)40. 
Among the genes encoding the core PRC2 subunits40 (EED, EZH1, EZH2, SUZ12, RBBP4 
and RBBP7), SUZ12 mRNA levels were downregulated in the metastatic cells (P = 0.009), 
although the fold change in the 786-O system did not qualify for the 155 gene set. The 
metastatic cells expressed lower levels of SUZ12 protein, whereas both the parental and 
metastatic cells expressed similar levels of EZH2 (Fig. 6a). ChIP-qPCR experiments reveled 
that SUZ12 binding was reduced at the CXCR4 promoter of 786-M1A cells (Fig 6b). Low 
levels of SUZ12 expression correlated also with ccRCC progression (Fig. 6c). The RMS50-
positive tumors in the TCGA cohort had both higher expression of CXCR4 (P = 5.2 × 10−7) 
and lower expression of SUZ12 (P = 8.3 × 10−9).
Knockdown of SUZ12 in the 786-O cells led to a reduction in H3K27me3 at the CXCR4 
promoter (Fig. 6d and Supplementary Fig. 19a) and a proportional increase in CXCR4 
expression (Fig. 6e). The SUZ12 knockdown cells displayed an enhanced metastatic 
phenotype in vivo (Fig. 6f). CXCR4 expression was also increased with a reduction in 
H3K27me3 when EZH1 and EZH2 were knocked down together but not individually (Fig. 
6g and Supplementary Fig. 19b,d), in line with previous reports showing functional 
redundancy of EZH1 and EZH241–43.
We then analyzed the transcriptome-wide effects of 5DC and SUZ12 knockdown, 
respectively, in the 786-O system (Supplementary Fig. 20a,b, Supplementary Tables 3 and 
4). This revealed a significant overlap between the 155 gene set and genes regulated by 
DNA methylation or by SUZ12. The majority of gene expression changes caused by 5DC or 
SUZ12 knockdown was not part of the 155 gene set, however, indicating the involvement of 
additional factors imposing selectivity.
DISCUSSION
Here we show that repressive chromatin modifications and DNA methylation restrict the 
expression of metastasis-associated VHL-HIF target genes, and that liberation from these 
constrains mediates ccRCC metastasis. The transcriptional output of the VHL-HIF pathway 
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thus evolves during ccRCC progression to further enhance the metastatic potential of the 
pathway (Figure 6h). These findings provide insights into the interplay between genetic and 
epigenetic mechanisms in the selection of metastatic traits.
The role of the VHL-HIF pathway in ccRCC initiation is well-established5, and the VHL-
HIF target CXCR4 has been proposed to drive ccRCC metastasis as well6. Clinical data 
suggests, however, that VHL-HIF activation does not automatically lead to the activation of 
metastasis genes21. Our data shows that a metastatic subprogram of the VHL-HIF pathway 
is activated only in a subpopulation of cancer cells in renal tumors. We find that CXCR4 and 
CYTIP are important mediators of the metastatic phenotype driven by the altered VHL-HIF 
response. CXCR4 has been previously implicated in the metastatic progression of other 
cancers1,17,18, and CXCL12, the ligand for CXCR4 and CXCR7, can attract ccRCC cells as 
well6, results confirmed in our model system. We identified additional genes that follow 
similar expression patterns, one of which is the intracellular signal modulator CYTIP. Our 
work establishes a novel role for CYTIP in supporting survival under stressed conditions, 
and points at additional HIF target genes for future studies.
The pathways that drive metastasis are often considered separate from tumor-initiating 
functions4. In the case of ccRCC, the major tumor-initiating pathway is also exploited for 
the acquisition of metastatic traits. The central role of the VHL-HIF pathway as a gatekeeper 
for renal tumorigenesis makes ccRCC an ideal model system for studying the connection 
between metastatic phenotypes and tumor-initiating mechanism. It is likely that the 
phenotypes of other tumor-initiating pathways may also expand to cover metastatic 
functions. The general concept emerging from this work could therefore have implications 
for our understanding of the evolution of metastatic traits in other cancers as well.
ONLINE METHODS
Cell lines
We obtained 786-O from ATCC, RFX-631 cells from National Cancer Institute, and OS-
RC-2 cells from RIKEN Cell Bank (Japan), and cultured in RPMI1640. For retrovirus and 
lentivirus production, GPG29 and 293T cells, respectively, were cultured in DMEM. 
RPMI1640 and DMEM contained 10% FBS, L-Glutamine (2 mM), penicillin (100 IU ml−1), 
streptomycin (100 μg ml−1) and amphotericin B (1 μg ml−1). In addition, the GPG29 
medium contained G418 (0.3 mg ml−1), doxycycline (20 ng ml−1) and puromycin (2 μg 
ml−1).
Overexpression and RNAi
For CXCR4 and CYTIP cDNA overexpression, we used the pBABE-puro retroviral 
expression vector. The pBABE-HA-VHL plasmid was generated by the Kaelin lab44 and 
obtained from Addgene (plasmid 19234). We used empty pBABE vector as control. Virus 
production in the GPG29 packaging cells followed published protocols45. The virus-
containing supernatant was then concentrated by ultracentrifugation, resuspended in RPMI 
medium and used for infection in the presence of polybrene (8 μg ml−1). Puromycin 
selection started the following day (4 μg ml−1). Similarly, we used a triple modality 
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retroviral reporter plasmid to stably label cells for bioluminescence imaging46, followed by 
selection of GFP-positive by FACS.
For RNAi-mediated gene silencing, we obtained clones and corresponding empty vectors 
from Open Biosystems. For EZH1, we used DNA oligos for the cloning of miR30-based 
shRNA constructs into the pGIPZ and pHAGE-puro vectors47. The clone numbers and oligo 
sequences are listed in Supplementary Table 5.
For HIF2α knockdown, we produced retrovirus as described above. For lentivirus 
production, we infected 293T cells with the shRNA-containing plasmid together with the 
packaging plasmids psPAX2 and pMD2.G using Lipofectamine 2000 (Invitrogen). We 
harvested virus 48 hours after transfection, then filtered and used it to infect target cells in 
the presence of polybrene (8 μg ml−1). Puromycin selection started the following day (4 μg 
ml−1). We used the corresponding empty vector as a control (pLKO.1 for CYTIP, pGIPZ for 
CXCR4, LTBP1 and SUZ12). For combination knockdown, we added two different viral 
supernatants into the same transduction mix. Correspondingly, the control for combination 
knockdown experiments contained both pLKO.1 and pGIPZ empty vectors.
Animal studies and isolation of metastatic cells
We performed all animal experiments in accordance with a protocol approved by MSKCC 
Institutional Animal Care and Use Committee. For in vivo selection, we inoculated cells 
(400,000) resuspended in 100μl of PBS into the lateral tail vein of 5–7 week old male NOD/
SCID mice. We followed tumor growth by bioluminescence imaging of anesthetized mice 
(100 mg kg−1 ketamine and 10 mg kg−1 xylazine) by injecting retro-orbitally d-luciferin 
(150 mg kg−1) and imaging with the IVIS Spectrum Xenogen machine (Caliper Life 
Sciences). When growing signal was observed for several weeks, we harvested lungs, 
dissected tumor nodules from the lungs, minced and placed them in RPMI supplemented 
with 0.125% collagenase III and 0.1% hyaluronidase. Samples were then gently rocked in 
37°C for 3–4 hours, briefly centrifuged and resuspended in 0.25% trypsin for ten minutes 
with vortexing every 2 minutes. We then centrifuged cells and plated them in RPMI 
medium. After reaching confluency, GFP-positive cells were sorted by FACS, and 
reinjected into mice. For the comparison of parental and metastatic cells in the lung 
colonization assays, we injected 150,000 cells (except for 786-M1B cells, for which three 
mice were injected with 150,000 cells and four mice with 400,000 cells). In all subsequent 
lung colonization assays, we used 150,000 cells. For bone and brain metastasis assays, we 
injected cells (100,000) into the left vetricle of 5–7 week old anesthetized athymic male 
nude mice. We monitored metastatic colonization by bioluminescence and X-ray imaging. 
For orthotopic renal subcapsular injections, we mixed cells with Matrigel. Incisions were 
made into the left flank of anesthetized mice and the left kidneys were exposed. Ten 
microliters of Matrigel containing 15,000 cells were carefully injected under the renal 
capsule and the incision was sutured. We confirmed the injections were confirmed by 
bioluminescent imaging. We confirmed brain metastases as well as lung metastasis after 
orthotopic injections by ex vivo imaging. For drug experiments, we purchased AMD3100 
from Sigma and injected the drug intraperitoneally twice daily (2.5 mg kg−1).
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Histological analysis and immunostaining
After being sacrificed, mice were perfused with 4% paraformaldehyde. Target organs were 
collected and fixed over night in 4% paraformaldehyde, washed, embedded in paraffin and 
sectioned. Haematoxylin-eosin staining was performed by standard methods. The MSKCC 
Molecular Cytology Core Facility performed immunostaining for GFP (Abcam) according 
to standard methods.
In vitro assays
For proliferation assays, we plated cells (500 per well) on 96-well plates and measured 
growth using the Resazurin reagent (R&D Systems) according to the manufacturer’s 
instructions. We read the signal using a plate reader, each time point in eight independent 
wells. For cell migration assays, we starved cells starved over night (0.2% FBS containing 
media). The next day, we plated 50,000 cells on Fluoroblock cell culture inserts (BD Falcon) 
with 8μm pores placed in control, recombinant human CXCL12 (R&D) or CXCL12 + 
AMD3100 (Sigma) containing media. Fourteen hours later the cells were fixed and stained 
with DAPI. Migration to the basolateral side of the membrane (nuclei stained with DAPI) 
was quantified using ImageJ software (three random fields for replicate wells) from images 
obtained by AMG Evos FL microscope. We quantified cell survival by the CellTiter-Glo 
cell viability assay (Promega). We plated cells (100,000) on 6-well plates with no serum, 
adding recombinant human TRAIL (PeproTech) the next day, and measuring cell survival 
two days later.
DNA Sequencing
The MSKCC DNA sequencing core facility sequenced VHL by capillary sequencing using 
previously published primers sequences were48. SETD2, JARID1C, UTX and PBRM1 
capillary sequencing was performed in the MSKCC Beene Translational Oncology Core 
Facility.
mRNA and protein detection
We extracted total RNA using PrepEase RNA spin kit (USB). RNA (1 μg) was used to 
generate cDNA with Transcriptor First Strand cDNA Synthesis Kit (Roche). For 
quantitative PCR, we used predesigned Taqman gene expression assays (Applied 
Biosystems) and the ABI 7900HT Fast Real-Time PCR System. TBP served as a 
housekeeping control gene in the analysis peformed by the SDS2.2.2 software (Applied 
Biosystems). For immunoblotting, we washed cells with PBS and lysed them using RIPA 
buffer. Proteins were separated by SDS-PAGE, transferred to PVDF membranes and blotted 
with antibodies recognizing HIF2α (NB100-122, Novus Biologicals), EZH2 (Cat. 612666, 
BD Biosciences), SUZ12 (ab12073, Abcam), Erk (9102S, Cell Signaling), pERK (4370S, 
Cell Signaling), CYTIP (SAB4200043-25UL, Sigma), α-tubulin (11H10, Cell Signaling). 
Secondary antibodies were HRP (Pierce) or fluorescence (LiCor) conjugated. 
Immunofluorescence of CXCR4 was performed with the MAB173 antibody (R&D).
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Clinical ccRCC samples
We collected a set of 91 surgically removed primary ccRCC specimens at our institution 
according to a protocol approved by the MSKCC Institutional Review Board and Human 
Biospecimen Utilization Committee. Samples were snap-frozen and DNA and RNA were 
extracted by standard methods.
mRNA expression analysis of clinical ccRCC samples
Direct assessment of CXCR4 mRNA expression was performed by the nCounter Analysis 
System (NanoString Technologies) according to manufacturer’s recommendations. The 
method is based on a solution-phase hybridization protocol that allows direct detection of 
target mRNA molecules in small amounts of input RNA. After data preprocessing and 
background correction, each sample was normalized for RNA loading using the ribosomal 
genes RPL13A, RPL24, RPL27, and RPS20. All 91 RNA samples passed the initial data 
quality control criteria.
DNA methylation analysis
The effects of DNA methylation on gene expression was studied by treating cells with 5′-
aza-deoxycytidine (5DC) followed by quantitative RT-PCR. A concentration of 100 nM was 
used in all experiments. MSKCC Beene Translational Oncology Core Facility carried out 
analysis of CpG methylation using the EpiTyper system (Sequenom, San Diego, CA), which 
performs quantitative analysis of DNA methylation using base-specific cleavage of bisulfite-
treated DNA and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) 
mass spectrometry. One μg of DNA was subjected to bisulfite treatment using the EZ-96 
DNA methylation Kit following the manufacturer’s instructions (Zymo Research, Orange, 
CA). Specific PCR primers with T7-promoter tags were designed using the EpiDesigner 
software (www.epidesigner.com). After polymerase chain reaction (PCR) and shrimp 
alkaline phosphatase (SAP)-treatment, in vitro transcription and T cleavage were carried out 
using the MassCleave kit (Sequenom). Epityper reaction product was then loaded onto a 
SpectroCHIP II array (Sequenom) and analyzed using a Bruker Biflex III MALDI-TOF 
mass spectrometer (SpectroREADER, Sequenom). Results were analyzed using the Epityper 
Analyzer software, and manually inspected for spectra quality and peak quantification. Of 
the clinical samples, 78 passed the quality control criteria and were used for further analysis.
DNase 1 sensitivity assays
We assessed chromatin accessibility as a function of DNase 1 sensitivity, following 
previously published protocols with modifications49,50. Cells were trypsinized and counted, 
washed once with PBS and resuspended in 500μl of ice-cold RSB buffer (10 mM Tris-HCl, 
pH 7.4, 10 mM NaCl, 3 mM MgCl2). Cells were lysed by slowly adding 8 ml of cold lysis 
buffer (RSB supplemented with 0.1% IGEPAL CA-630) and incubating on ice for ten 
minutes. Nuclei were pelleted by centrifuging five minutes at 500 g, washed once with 5 ml 
of cold RSB, resuspended in DNase 1 reaction buffer (Roche) at a ~7 × 106 ml−1 
concentration and aliquoted into multiple tubes. Treatment with recombinant DNase 1 was 
carried out at 37°C for 20 minutes and the reaction was stopped by adding an equal volume 
of stop buffer (0.1 M NaCl, 0.1% (w vol−1) SDS, 50 mM Tris-HCl (pH 8.0), 100 nM 
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EDTA). Samples were then treated with proteinase K over night and DNA was extracted 
using the DNeasy Blood & Tissue Kit (Qiagen). The DNase 1 digestion was first optimized 
by testing several different concentrations (10–200U per 180 μl reaction). For final 
experiments, we performed 3–4 DNase treatments with the same concentration. We 
quantified DNA by PCR using the SYBR Green Mix (Thermo Scientific) and ABI 7900HT 
Fast Real-Time PCR System absolute quantification method. DNase insensitive control loci 
(Chr15at22Mb and Chr17at17Mb) that were randomly chosen based on DNase data from 
multiple cell lines available at the UCSC genome browser (http://genome.ucsc.edu/) and 
empirically validated as regions showing minimal sensitivity to DNase when compared to 
non-treated controls served as normalization controls. PCR primers listed in Supplementary 
Table 6.
Chromatin Immunoprecipitation (ChIP)
For ChIP, we used the ChIP Assay Kit (Millipore) according to the manufacturer’s 
instructions. Cells were sonicated in 20 second pulses for a total of 3 min 20 s. The 
following antibodies were used: H3K4me3 (04-745, Millipore), H3K27me3 (17-622, 
Millipore), SUZ12 (ab12073, Abcam). Control experiments were done without antibody. 
DNA was extracted using the QIAquick PCR Purification Kit (Qiagen) followed by 
quantitative PCR essentially as described above for DNase sensitivity assays.
Gene expression profiling
We extracted total RNA using the PrepEase RNA spin kit (USB). MSKCC Genomics Core 
Facility prepared the samples according to standard protocols and hybridized them on 
Affymetrix HG-U133A or HG-U133 Plus 2.0 microarrays. We processed the data using 
GCRMA together with updated probe set definitions (hs133phsentrezg)51. Differentially 
expressed genes between groups were identified with fold-change (<0.5 or >2) and t-test (P 
< 0.05) cutoffs. From the initial comparison of the parental 786-O cells to the metastatic 
derivatives, we identified 155 genes (the 155 gene set).
Bioinformatic analysis
We conducted all bioinformatic analyses using R. The following data sets were used: 
GSE2109 (192 ccRCC samples), GSE3538 (Ref. 25), GSE17895 (Ref. 30), TCGA52. 
GSE2109 was processed as described above for the cell line data. For GSE3538 and 
GSE17895, preprocessed data was downloaded from the Stanford Microarray Database 
(http://smd.stanford.edu, normalized log2 ratio, >70% good data), and from GEO, 
respectively. For GSE3538, missing values were imputed with the k-nearest neighbors 
method, using the 10 neighboring genes. For the TCGA data set, normalized mRNA z-
scores were downloaded from the TCGA cBio portal52. Differentially expressed genes 
between groups were identified by fold-change and t-test without the equal variance 
assumption (P < 0.05).
We performed unsupervised hierarchical clustering using gene Z-scores and the function 
heatmap.2 in the R-package gplots. To find the most suitable method for clustering, we 
compared three different algorithms (Pearson’s correlation coefficient, Spearman’s 
correlation coefficient and Kendall’s correlation coefficient) to calculate correlation between 
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samples using the 155 gene set in the GSE2109 data set. As a measure of cluster 
reproducibility, we calculated R-indices as described53. Pearson’s correlation coefficient 
yielded the highest R-indices for multiple cutoff levels (number of clusters), and was thus 
selected for all subsequent analysis.
155 gene set-positive tumors were identified by unsupervised hierarchical clustering. Visual 
inspection revealed a clear cluster in all three data sets: TCGA, GSE2109 and GSE3538. 
RMS50, a derivative of the 155 gene set, was generated by using the GSE2109 data set and 
including genes that fulfilled the following criteria: upregulated in the metastatic derivatives 
and higher expression in the 155 gene set-positive cluster, or downregulated in the 
metastatic derivatives and lower expression in 155 gene set-positive cluster.
For categorical data (RMS50 status), differences in survival between groups were evaluated 
using the log-rank test. For continuous variables (CYTIP methylation data, CXCR4 mRNA 
expression, SUZ12 mRNA expression), a Cox proportional hazards model was utilized as 
implemented in the coxph function in the R-package survival.
ChIP-seq library preparation
Subconfluent cells were cross-linked (1% formaldehyde, 10 min), quenched (200 mM 
Glycine, 5 min), washed with ice-cold PBS and harvested by scraping. ChIP was performed 
essentially as described54. ChIP library was prepared for sequencing by the SOLiD 4 
(H3K4me3) or HiSeq2000 (H3K27me3) instruments according to manufacturer 
recommended procedures.
STAMP assay library preparation
Genomic DNA was randomly fragmented to a modal length of 120 bp and then methylated 
DNA was enriched and processed for massively parallel sequencing using the sequence tag 
analysis of DNA methylation patterns (STAMP) method55. MBD-enriched fragment 
libraries were sequenced using SOLiD 4.
ChIP-seq and STAMP Data Analysis
Sequenced fragments were mapped to Hg18 and genomic coverage maps were generated by 
extending single-end reads to the modal fragment length or based upon mapping of paired-
ends as described55. Coverage maps were normalized to the total library size and were then 
used to evaluate relative enrichment near each Refseq transcription start site (± 5,000 bp). 
The significance of differential coverage was estimated by counting tags within 100 bp 
windows tiled across the regions of interest and then estimating the significance of 
differential tag counts using empirical Bayes estimation and exact tests based on the 
negative binomial distribution56.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Experimental Model System and Gene Expression Signature for ccRCC Metastasis
a. Quantification of lung photon flux (photons per second) normalized to day 0 after tail 
vein inoculation of cancer cells. n = 6–9 for all groups. P-value calculated by the two-tailed 
Wilcoxon rank sum test. Error bars represent standard error of the mean.
b. Lung photon flux ex vivo 66 days after renal subcapsular inoculation of cells. n = 5 for 
786-O cells, n = 4 for 786-M1A cells. P-value calculated by the two-tailed Wilcoxon rank 
sum test.
c. H&E staining of histological sections. Orthotopic tumor formed by 786-O cells (top). 
Orthotopic tumor formed by 786-M1A cells (middle). Lung metastasis formed by 786-M1A 
cells (bottom).
d. Normalized photon flux from hind limbs after intracardiac inoculation of cells. n = 9–10 
for all groups. P-value calculated by the two-tailed Wilcoxon rank sum test. Error bars 
represent standard error of the mean.
e. X-ray image of a bone metastasis formed by the 786-M1A cells.
f. Normalized photon flux from whole brains imaged ex vivo at day 64 after intracardiac 
inoculation of cells. The arrow indicates the sample from which the histological section 
shown in (g) was derived.
g. Whole brain section and a close-up showing immunohistochemical staining of a brain 
metastasis using an anti-GFP antibody. Scale bar in the insert, 0.2 mm.
h. Disease-specific survival for RMS50-positive and RMS50-negative tumors in the TCGA 
data set. n = 389. P-value calculated by the log-rank test.
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Figure 2. VHL-HIF Signal Output Modulation Associated with ccRCC Progression
a. Effects of VHL reintroduction on CXCR4 expression measured by quantitative RT-PCR 
analysis. Expression normalized to 786-O cells transduced with the control vector.
b. Kaplan-Meier analysis of metastasis-free survival in patients with ccRCC. Classification 
based on CXCR4 mRNA expression in primary ccRCCs, top 1/3 shown in red, bottom 2/3 in 
blue. P-value from a Cox proportional hazards model with CXCR4 expression treated as a 
continuous variable. n = 91.
c. Effects of VHL reintroduction on VEGFA and ADM expression measured by quantitative 
RT-PCR analysis. Expression normalized to 786-O cells transduced with the control vector.
d. Venn-diagram showing the overlap between the 155 metastasis-associated genes and 
genes changed after VHL reintroduction into the 786-M1A cells. Statistical significance of 
overlap tested by Fisher’s exact test.
e. Effects of VHL reintroduction on gene expression measured by quantitative RT-PCR 
analysis. Expression normalized to 786-O cells transduced with the control vector.
f. Effects of HIF2α knockdown on gene expression measured by quantitative RT-PCR 
analysis in 786-M1A cells. Expression normalized to the cells transduced with the hairpin 
control vector.
g. Effects of VHL reintroduction on gene expression measured by quantitative RT-PCR 
analysis. Expression normalized to RFX-631 cells transduced with the control vector.
h. Effects of VHL reintroduction on gene expression measured by quantitative RT-PCR 
analysis. Expression normalized to OS-LM1 cells transduced with the control vector.
i. A schematic summarizing the hypothesis that when VHL loss stabilizes HIF, early ccRCC 
genes such as VEGF and ADM are highly expressed whereas the activation of pro-metastatic 
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HIF target genes such as CXCR4 and others requires additional amplifying mechanisms. 
Error bars represent the 95% confidence interval based on multiple PCR reactions in all 
panels.
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Figure 3. VHL-HIF Pathway Modulation Activates Functional Mediators of ccRCC Metastasis
a. Normalized bioluminescence photon flux of the lungs with and without reintroduced VHL 
at day 28 after tail vein inoculation of cancer cells. For 786-M1A-VHL cells n = 4, for all 
other groups n = 5.
b. Normalized bioluminescence photon flux of the lungs at day 28 after tail vein inoculation 
of 786-M1A cells with CYTIP and CXCR4 knockdown individually or in combination. 
Control (n = 25) is a pool of the following groups: pLKO.1 n = 5, pGIPZ n = 10, pLKO.1/
pGIPZ n = 10. For CYTIPsh1/CXCR4sh1 n = 10, for all other groups n = 5.
c. Normalized bioluminescence photon flux of the lungs at day 64 after tail vein inoculation 
of 786-O cells with transduced CYTIP or CXCR4 cDNA. n = 5 per group.
d. Normalized bioluminescence photon flux of the lungs at day 49 after tail vein inoculation 
of OS-LM1 cells with CYTIP and CXCR4 double knockdown. Control (pLKO.1/pGIPZ) n 
= 8, CYTIPsh1/CXCR4sh1 n = 7.
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e. Effects of CXCL12 on cancer cell migration measured by the Boyden chamber assay. 
AMD, the CXCR4 inhibitor AMD3100. Error bars represent standard deviation of the mean.
f. Normalized bioluminescence photon flux of the lungs at day 28 after tail vein inoculation 
of 786-M1A cells. Mice treated with AMD3100 or PBS. n = 5 for both groups.
g. Normalized photon flux from hind limbs after intracardiac inoculation of 786-M1A cells 
with CYTIP knockdown. n = 9–10 for all groups.
h. Effects of CYTIP inhibition on 786-M1A cell survival under TRAIL treatment in low 
confluency and low serum conditions. Error bars represent standard deviation of the mean.
P-value calculated by the two-tailed Wilcoxon rank sum test (a–d, f, g) or the two-tailed 
Student’s t-test (e, h).
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Figure 4. DNA Demethylation Activates CYTIP Expression in Metastatic ccRCC
a. Average enrichment of DNA methylation near the 772 genomic loci that showed the 
greatest difference in DNA methylation between the 786-O and 786-M1A cells plotted for 
both 786-O cells (black solid line) and 786-M1A cells (red solid line). The black and red 
dashed lines show the average enrichment plus 1 SD for 786-O and 786-M1A cells, 
respectively. DMR, differentially methylated region.
b. Enrichment of methylated DNA around (± 2,000 bp) CYTIP TSS as determined by 
STAMP analysis. Y-axis shows the relative counts of high-throughput sequencing reads 
recovered after enrichment for methylated DNA. The dashed black line indicates an estimate 
of significance of difference in enrichment between 786-O and 786-M1A cells as 
determined by a negative binomial error model. The black circles below the x-axis are CpG 
positions. The first CYTIP exon is in tan, intron in light blue with transcription direction 
indicated by hatching. The metastatic cells show a value of zero throughout the region.
c. Gene expression measured by quantitative RT-PCR analysis of the 786-O cells with or 
without VHL reintroduction. Cells were treated with either 5DC or vehicle (dimethyl 
sulfoxide). Error bars represent the 95% confidence interval based on multiple PCR 
reactions.
d. DNA methylation at CXCR4 promoter in clinical ccRCC samples (n = 78) grouped by 
tumor grade. The CpG dinucleotides analyzed correspond to the ones highlighted in red in 
Supplementary Figure 15b.
e. CYTIP DNA methylation in clinical ccRCC samples (n = 78) grouped by tumor grade. 
(***) P < 0.001, (**) P < 0.01. (*) P < 0.05, linear regression analysis. The CpG 
dinucleotides analyzed correspond to the ones highlighted in blue in panel Supplementary 
Figure 15b.
f. Kaplan-Meier analysis of overall survival in patients with ccRCC. Classification based on 
average CYTIP methylation, top 1/3 shown in red, bottom 2/3 in blue. P-value from a Cox 
proportional hazards model with average CYTIP methylation treated as a continuous 
variable. n =78.
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Figure 5. Histone Modification Patterns Linked to ccRCC Progression
a. Normalized H3K4me3 ChIP-seq signal relative to CXCR4 and CYTIP TSS.
b. Normalized H3K27me3 ChIP-seq signal relative to CXCR4 and CYTIP TSS.
c. H3K4me3 chromatin immunoprecipitation followed by quantitative PCR analysis at the 
CXCR4 and CYTIP loci. Error bars denote standard deviation.
d. H3K27me3 chromatin immunoprecipitation followed by quantitative PCR analysis at the 
CXCR4 and CYTIP loci. Error bars denote standard deviation.
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Figure 6. Loss of PRC2-Dependent Repression Activates CXCR4 Expression in Metastatic 
ccRCC
a. Top, SUZ12 and EZH2 protein levels measured by immunoblotting. Bottom, 
quantification of signal normalized to the loading control tubulin.
b. SUZ12 chromatin immunoprecipitation followed by quantitative PCR analysis at the 
CXCR4 and CYTIP loci. Error bars denote standard deviation.
c. Kaplan-Meier analysis of overall survival in patients with ccRCC from the TCGA data 
set. Classification based on SUZ12 expression, top 70% shown in red, bottom 30% in blue. 
P-value from a Cox proportional hazards model with SUZ12 expression treated as a 
continuous variable. n = 389.
d. H3K27me3 chromatin immunoprecipitation followed by quantitative PCR analysis at the 
CXCR4 and CYTIP loci. Error bars denote standard deviation.
e. CXCR4 expression measured by quantitative RT-PCR analysis after SUZ12 knockdown. 
Error bars represent 95% confidence interval based on multiple PCR reactions.
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f. Lung colonization of 786-O cells after SUZ12 knockdown. Normalized bioluminescence 
photon flux of the lungs at day 68. n = 7–10. P-value calculated using the two-tailed 
Wilcoxon rank-sum test.
g. CXCR4 expression measured by quantitative RT-PCR analysis after combinatorial 
knockdown of both EZH1 and EZH2. Error bars represent 95% confidence interval based on 
multiple PCR reactions.
h. Model. VHL loss initiates renal tumorigenesis by stabilizing HIF2α, which leads to the 
activation of several target genes, such as VEGFA. At this stage, many potential VHL-HIF 
target genes are only weakly expressed due to various inhibitory mechanisms (e.g. DNA 
methylation and PRC2-dependent repression). Changes in the epigenetic landscape can 
allow hyperinduction of VHL-HIF target genes. If these genes are beneficial to the tumor 
(e.g. CXCR4 and CYTIP), they will drive ccRCC progression and get selected for.
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